BrainStorm Q2 2026 net loss $3.9M, cash down to $0.2M; advances NurOwn Phase 3b

BRAINSTORM CELL THERAPEUTICS INC.

Q2 2026 net loss $3.9M vs $2.9M in Q2 2025; EPS -$0.35 vs -$0.34.
Cash, equivalents, restricted cash $0.2M at June 30, 2026, down from $1.03M a year earlier.
G&A jumped to $2.7M from $1.5M; R&D was ~$1.0M vs $1.1M.
Phase 3b ENDURANCE trial of NurOwn in ALS planned for ~200 patients under FDA SPA; Peter Pitts named Executive Chairman.
Raised $400k in May 2026 private placement; H1 2026 total capital ~$2.4M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.